<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02173379</url>
  </required_header>
  <id_info>
    <org_study_id>10-392 C</org_study_id>
    <nct_id>NCT02173379</nct_id>
  </id_info>
  <brief_title>Absorb IV Randomized Controlled Trial</brief_title>
  <official_title>A Clinical Evaluation of Absorb™ BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects With de Novo Native Coronary Artery Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      ABSORB IV is a prospective, randomized (1:1, Absorb BVS to XIENCE), single-blind,
      multi-center study, registering approximately 2610 subjects from approximately 140 sites in
      the United States and outside the United States. ABSORB IV is a continuation of ABSORB III
      (NCT01751906) trial which are maintained under one protocol because both trial designs are
      related. The data from ABSORB III and ABSORB IV will be pooled to support the ABSORB IV
      primary endpoint. Both the trials will evaluate the safety and effectiveness of Absorb BVS.

      The ABSORB IV Randomized Controlled Trial (RCT) is designed to continue to evaluate the
      safety and effectiveness as well as the potential short and long-term benefits of Abbott
      Vascular Absorb™ Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
      (once commercially available), as compared to the commercially approved, control stent
      XIENCE.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ABSORB IV:

      A. Primary Objective:

        -  To evaluate 30-day clinical outcomes of the Absorb BVS compared to XIENCE in the
           treatment of subjects with ischemic heart disease caused by up to three de novo native
           coronary artery lesions in a maximum of two epicardial vessels, with a maximum of two
           lesions per epicardial vessel.

        -  To evaluate long-term clinical outcomes of Absorb BVS compared to XIENCE in the
           treatment of subjects with ischemic heart disease caused by up to three denovo native
           coronary artery lesions in a maximum of two epicardial vessels, with a maximum of two
           lesions per epicardial vessel.

      B. Secondary Objectives:

        -  To evaluate 1-year clinical outcomes of the Absorb BVS compared to XIENCE in the
           treatment of subjects with ischemic heart disease caused by up to three de novo native
           coronary artery lesions in a maximum of two epicardial vessels, with a maximum of two
           lesions per epicardial vessel.

        -  To evaluate the incidence of angina occurring within 1 year, with treatment of Absorb
           BVS compared to XIENCE.

      The enrollment of the 2610 subjects in ABSORB IV will start after enrollment completion of
      the 2000 primary analysis subjects in ABSORB III. All registered subjects will have clinical
      follow-up at 30, 90, 180, 270 days and 1, 2, 3, 4 and 5 years.

      Note: All registered subjects in ABSORB IV will be followed up to 5 years via telephone
      contact/office visit if it is necessary as determined by the Sponsor.

      In addition, all 2610 subjects in ABSORB IV will complete patient-reported outcome (PRO)
      self-administered questionnaires at baseline, 30 days,180 days, 1 year, 3 years and 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 2014</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Target Lesion Failure (TLF)</measure>
    <time_frame>30 days</time_frame>
    <description>Target lesion failure (TLF) composite of Cardiac Death, Myocardial Infarction attributable to Target Vessel (TV-MI), or Ischemia-Driven Target Lesion Revascularization (ID-TLR))</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Powered TLF, Tested for Non-inferiority of Absorb BVS to XIENCE</measure>
    <time_frame>1 year</time_frame>
    <description>This analysis will consist of ~2610 subjects in ABSORB IV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Powered Angina</measure>
    <time_frame>30 days</time_frame>
    <description>Angina is defined as any angina or angina equivalent symptoms determined by the physician and/or research coordinator after interview of the patient, and as adjudicated by a clinical events committee (CEC).
This analysis will exclude angina or angina equivalent symptoms that occurred following the index procedure through hospital discharge or 7 days, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Target Lesion With Acute Success- Device Success (Lesion Level Analysis)</measure>
    <time_frame>In-hospital (≤ 7days)</time_frame>
    <description>Successful delivery and deployment of the study scaffold/stent at the intended target lesion and successful withdrawal of the delivery system with attainment of final in-scaffold/stent residual stenosis of less than 30% by quantitative coronary angiography (QCA) (by visual estimation if QCA unavailable). When bailout scaffold/stent is used, the success or failure of the bailout scaffold/stent delivery and deployment is not one of the criteria for device success.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Acute Success- Procedural Success (Subject Level Analysis)</measure>
    <time_frame>In-hospital (≤ 7days)</time_frame>
    <description>Achievement of final in-scaffold/stent residual stenosis of less than 30% by QCA (by visual estimation if QCA unavailable) with successful delivery and deployment of at least one study scaffold/stent at the intended target lesion and successful withdrawal of the delivery system for all target lesions without the occurrence of cardiac death, target vessel MI or repeat TLR during the hospital stay (maximum of 7 days).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Death (Cardiac, Vascular, Non-cardiovascular)</measure>
    <time_frame>In-hospital (≤ 7 days post index procedure)</time_frame>
    <description>Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Death (Cardiac, Vascular, Non-cardiovascular)</measure>
    <time_frame>30 days</time_frame>
    <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Death (Cardiac, Vascular, Non-cardiovascular)</measure>
    <time_frame>90 days</time_frame>
    <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Death (Cardiac, Vascular, Non-cardiovascular)</measure>
    <time_frame>180 days</time_frame>
    <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Death (Cardiac, Vascular, Non-cardiovascular)</measure>
    <time_frame>270 days</time_frame>
    <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Death (Cardiac, Vascular, Non-cardiovascular)</measure>
    <time_frame>1 year</time_frame>
    <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Death (Cardiac, Vascular, Non-cardiovascular)</measure>
    <time_frame>2 years</time_frame>
    <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Death (Cardiac, Vascular, Non-cardiovascular)</measure>
    <time_frame>3 years</time_frame>
    <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Death (Cardiac, Vascular, Non-cardiovascular)</measure>
    <time_frame>4 years</time_frame>
    <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Death (Cardiac, Vascular, Non-cardiovascular)</measure>
    <time_frame>5 years</time_frame>
    <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Myocardial Infarction (MI)</measure>
    <time_frame>In-hospital (≤ 7 days post index procedure)</time_frame>
    <description>Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Myocardial Infarction (MI)</measure>
    <time_frame>30 days</time_frame>
    <description>Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Myocardial Infarction (MI)</measure>
    <time_frame>90 days</time_frame>
    <description>Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Myocardial Infarction (MI)</measure>
    <time_frame>180 days</time_frame>
    <description>Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Myocardial Infarction (MI)</measure>
    <time_frame>270 days</time_frame>
    <description>Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Myocardial Infarction (MI)</measure>
    <time_frame>1 year</time_frame>
    <description>Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Myocardial Infarction (MI)</measure>
    <time_frame>2 years</time_frame>
    <description>Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Myocardial Infarction (MI)</measure>
    <time_frame>3 years</time_frame>
    <description>Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Myocardial Infarction (MI)</measure>
    <time_frame>4 years</time_frame>
    <description>Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Myocardial Infarction (MI)</measure>
    <time_frame>5 years</time_frame>
    <description>Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Lesion Revascularization (TLR)</measure>
    <time_frame>In-hospital (≤ 7 days post index procedure)</time_frame>
    <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Lesion Revascularization (TLR)</measure>
    <time_frame>30 days</time_frame>
    <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants withTarget Lesion Revascularization (TLR)</measure>
    <time_frame>90 days</time_frame>
    <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Lesion Revascularization (TLR)</measure>
    <time_frame>180 days</time_frame>
    <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Lesion Revascularization (TLR)</measure>
    <time_frame>270 days</time_frame>
    <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Lesion Revascularization (TLR)</measure>
    <time_frame>1 year</time_frame>
    <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Lesion Revascularization (TLR)</measure>
    <time_frame>2 years</time_frame>
    <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Lesion Revascularization (TLR)</measure>
    <time_frame>3 years</time_frame>
    <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Lesion Revascularization (TLR)</measure>
    <time_frame>4 years</time_frame>
    <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Lesion Revascularization (TLR)</measure>
    <time_frame>5 years</time_frame>
    <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Revascularization (TVR)</measure>
    <time_frame>In-hospital (≤ 7 days post index procedure)</time_frame>
    <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.
TVR includes all TVR, excluding TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Revascularization (TVR)</measure>
    <time_frame>30 days</time_frame>
    <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.
TVR includes all TVR, excluding TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Revascularization (TVR)</measure>
    <time_frame>90 days</time_frame>
    <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.
TVR includes all TVR, excluding TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Revascularization (TVR)</measure>
    <time_frame>180 days</time_frame>
    <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. classified as: Ischemic driven TVR and Non-ischemic driven TVR.
-TVR includes all TVR, excluding TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Revascularization (TVR)</measure>
    <time_frame>270 days</time_frame>
    <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.
TVR includes all TVR, excluding TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Revascularization (TVR)</measure>
    <time_frame>1 year</time_frame>
    <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.
TVR includes all TVR, excluding TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Revascularization (TVR)</measure>
    <time_frame>2 years</time_frame>
    <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.
TVR includes all TVR, excluding TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Revascularization (TVR)</measure>
    <time_frame>3 years</time_frame>
    <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.
TVR includes all TVR, excluding TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Revascularization (TVR)</measure>
    <time_frame>4 years</time_frame>
    <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.
TVR includes all TVR, excluding TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Revascularization (TVR)</measure>
    <time_frame>5 years</time_frame>
    <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.
TVR includes all TVR, excluding TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Coronary Revascularization</measure>
    <time_frame>In-hospital (≤ 7 days post index procedure)</time_frame>
    <description>Revascularization includes TLR, TVR excluding TLR, and non TVR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Coronary Revascularization</measure>
    <time_frame>30 days</time_frame>
    <description>Revascularization includes TLR, TVR excluding TLR, and non TVR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Coronary Revascularization</measure>
    <time_frame>90 days</time_frame>
    <description>Revascularization includes TLR, TVR excluding TLR, and non TVR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Coronary Revascularization</measure>
    <time_frame>180 days</time_frame>
    <description>Revascularization includes TLR, TVR excluding TLR, and non TVR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Coronary Revascularization</measure>
    <time_frame>270 days</time_frame>
    <description>Revascularization includes TLR, TVR excluding TLR, and non TVR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Coronary Revascularization</measure>
    <time_frame>1 year</time_frame>
    <description>Revascularization includes TLR, TVR excluding TLR, and non TVR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Coronary Revascularization</measure>
    <time_frame>2 years</time_frame>
    <description>Revascularization includes TLR, TVR excluding TLR, and non TVR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Coronary Revascularization</measure>
    <time_frame>3 years</time_frame>
    <description>Revascularization includes TLR, TVR excluding TLR, and non TVR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Coronary Revascularization</measure>
    <time_frame>4 years</time_frame>
    <description>Revascularization includes TLR, TVR excluding TLR, and non TVR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Coronary Revascularization</measure>
    <time_frame>5 years</time_frame>
    <description>Revascularization includes TLR, TVR excluding TLR, and non TVR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced All Death/All MI</measure>
    <time_frame>In-hospital (≤ 7 days post index procedure)</time_frame>
    <description>All deaths includes
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced All Death/All MI</measure>
    <time_frame>30 days</time_frame>
    <description>All deaths includes
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Death/All MI</measure>
    <time_frame>90 days</time_frame>
    <description>All deaths includes
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Death/All MI</measure>
    <time_frame>180 days</time_frame>
    <description>All deaths includes
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Death/All MI</measure>
    <time_frame>270 days</time_frame>
    <description>All deaths includes
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Death/All MI</measure>
    <time_frame>1 year</time_frame>
    <description>All deaths includes
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Death/All MI</measure>
    <time_frame>2 years</time_frame>
    <description>All deaths includes
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Death/All MI</measure>
    <time_frame>3 years</time_frame>
    <description>All deaths includes
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Death/All MI</measure>
    <time_frame>4 years</time_frame>
    <description>All deaths includes
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Death/All MI</measure>
    <time_frame>5 years</time_frame>
    <description>All deaths includes
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI</measure>
    <time_frame>In-hospital (≤ 7 days post index procedure)</time_frame>
    <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI</measure>
    <time_frame>30 days</time_frame>
    <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI</measure>
    <time_frame>90 days</time_frame>
    <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI</measure>
    <time_frame>180 days</time_frame>
    <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI</measure>
    <time_frame>270 days</time_frame>
    <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI</measure>
    <time_frame>1 year</time_frame>
    <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI</measure>
    <time_frame>2 years</time_frame>
    <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI</measure>
    <time_frame>3 years</time_frame>
    <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI</measure>
    <time_frame>4 years</time_frame>
    <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI</measure>
    <time_frame>5 years</time_frame>
    <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)</measure>
    <time_frame>In-hospital (≤ 7 days post index procedure)</time_frame>
    <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)</measure>
    <time_frame>90 days</time_frame>
    <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)</measure>
    <time_frame>180 days</time_frame>
    <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)</measure>
    <time_frame>270 days</time_frame>
    <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)</measure>
    <time_frame>1 year</time_frame>
    <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)</measure>
    <time_frame>2 years</time_frame>
    <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)</measure>
    <time_frame>3 years</time_frame>
    <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)</measure>
    <time_frame>4 years</time_frame>
    <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)</measure>
    <time_frame>5 years</time_frame>
    <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI/ID-TLR (Major Adverse Cardiac Events-MACE)</measure>
    <time_frame>In-hospital (≤ 7 days post index procedure)</time_frame>
    <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced With Cardiac Death/All MI/ID-TLR (MACE)</measure>
    <time_frame>30 days</time_frame>
    <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)</measure>
    <time_frame>90 days</time_frame>
    <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)</measure>
    <time_frame>180 days</time_frame>
    <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)</measure>
    <time_frame>270 days</time_frame>
    <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)</measure>
    <time_frame>1 year</time_frame>
    <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)</measure>
    <time_frame>2 years</time_frame>
    <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)</measure>
    <time_frame>3 years</time_frame>
    <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)</measure>
    <time_frame>4 years</time_frame>
    <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)</measure>
    <time_frame>5 years</time_frame>
    <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (Target Vessel Failure, TVF)</measure>
    <time_frame>In-hospital (≤ 7 days post index procedure)</time_frame>
    <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)</measure>
    <time_frame>30 days</time_frame>
    <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)</measure>
    <time_frame>90 days</time_frame>
    <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)</measure>
    <time_frame>180 days</time_frame>
    <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)</measure>
    <time_frame>270 days</time_frame>
    <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)</measure>
    <time_frame>1 year</time_frame>
    <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)</measure>
    <time_frame>2 years</time_frame>
    <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)</measure>
    <time_frame>3 years</time_frame>
    <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)</measure>
    <time_frame>4 years</time_frame>
    <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)</measure>
    <time_frame>5 years</time_frame>
    <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Death/All MI/All Revascularization (DMR)</measure>
    <time_frame>In-hospital (≤ 7 days post index procedure)</time_frame>
    <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Death/All MI/All Revascularization</measure>
    <time_frame>30 days</time_frame>
    <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Death/All MI/All Revascularization</measure>
    <time_frame>90 days</time_frame>
    <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Death/All MI/All Revascularization</measure>
    <time_frame>180 days</time_frame>
    <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Death/All MI/All Revascularization</measure>
    <time_frame>270 days</time_frame>
    <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Death/All MI/All Revascularization</measure>
    <time_frame>1 year</time_frame>
    <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Death/All MI/All Revascularization</measure>
    <time_frame>2 years</time_frame>
    <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Death/All MI/All Revascularization</measure>
    <time_frame>3 years</time_frame>
    <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Death/All MI/All Revascularization</measure>
    <time_frame>4 years</time_frame>
    <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Death/All MI/All Revascularization</measure>
    <time_frame>5 years</time_frame>
    <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Scaffold/Stent Thrombosis (Per Academic Research Consortium (ARC) Definition)</measure>
    <time_frame>Acute (0 - 24 hours post stent implantation)</time_frame>
    <description>Stent thrombosis was defined by Academic Research Consortium (ARC) criteria as definite (angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic ECG changes that suggest acute ischemia or typical rise and fall of cardiac biomarkers OR pathological confirmation at autopsy or via examination of tissue retrieved following thrombectomy), probable (any unexplained death within the first 30 days or, regardless of the time after the index procedure, any Myocardial infarction (MI) related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation and in the absence of any other obvious cause), and possible (any unexplained death from 30 days after intracoronary stenting until end of trial follow-up). Stent thrombosis was categorized as acute (0-24 hours post stent implantation), Subacute (&gt;24 hours to 30 days post stent implantation), late (&gt;30 days to 1 year post stent implantation).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Scaffold/Stent Thrombosis (Per ARC Definition)</measure>
    <time_frame>Subacute (&gt;24 hours - 30 days post stent implantation)</time_frame>
    <description>Stent thrombosis was defined by Academic Research Consortium (ARC) criteria as definite (angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic ECG changes that suggest acute ischemia or typical rise and fall of cardiac biomarkers OR pathological confirmation at autopsy or via examination of tissue retrieved following thrombectomy), probable (any unexplained death within the first 30 days or, regardless of the time after the index procedure, any Myocardial infarction (MI) related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation and in the absence of any other obvious cause), and possible (any unexplained death from 30 days after intracoronary stenting until end of trial follow-up). Stent thrombosis was categorized as acute (0-24 hours post stent implantation), Subacute (&gt;24 hours to 30 days post stent implantation), late (&gt;30 days to 1 year post stent implantation).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Scaffold/Stent Thrombosis (Per ARC Definition)</measure>
    <time_frame>Late (30 days - 1 year post stent implantation)</time_frame>
    <description>Stent thrombosis was defined by Academic Research Consortium (ARC) criteria as definite (angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic ECG changes that suggest acute ischemia or typical rise and fall of cardiac biomarkers OR pathological confirmation at autopsy or via examination of tissue retrieved following thrombectomy), probable (any unexplained death within the first 30 days or, regardless of the time after the index procedure, any Myocardial infarction (MI) related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation and in the absence of any other obvious cause), and possible (any unexplained death from 30 days after intracoronary stenting until end of trial follow-up). Stent thrombosis was categorized as acute (0-24 hours post stent implantation), Subacute (&gt;24 hours to 30 days post stent implantation), late (&gt;30 days to 1 year post stent implantation).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Scaffold/Stent Thrombosis (Per ARC Definition)</measure>
    <time_frame>Very late (&gt;1 year post stent implantation)</time_frame>
    <description>Stent thrombosis was defined by Academic Research Consortium (ARC) criteria as definite (angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic ECG changes that suggest acute ischemia or typical rise and fall of cardiac biomarkers OR pathological confirmation at autopsy or via examination of tissue retrieved following thrombectomy), probable (any unexplained death within the first 30 days or, regardless of the time after the index procedure, any Myocardial infarction (MI) related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation and in the absence of any other obvious cause), and possible (any unexplained</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Rehospitalization</measure>
    <time_frame>30 days</time_frame>
    <description>Coronary artery disease (CAD) related
Cardiovascular, non-CAD related
Non-cardiovascular related</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Rehospitalization</measure>
    <time_frame>90 days</time_frame>
    <description>CAD related
Cardiovascular, non-CAD related
Non-cardiovascular related</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Rehospitalization</measure>
    <time_frame>180 days</time_frame>
    <description>CAD related
Cardiovascular, non-CAD related
Non-cardiovascular related</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Rehospitalization</measure>
    <time_frame>270 days</time_frame>
    <description>CAD related
Cardiovascular, non-CAD related
Non-cardiovascular related</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Rehospitalization</measure>
    <time_frame>1 year</time_frame>
    <description>CAD related
Cardiovascular, non-CAD related
Non-cardiovascular related</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Rehospitalization</measure>
    <time_frame>2 years</time_frame>
    <description>CAD related
Cardiovascular, non-CAD related
Non-cardiovascular related</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Rehospitalization</measure>
    <time_frame>3 years</time_frame>
    <description>CAD related
Cardiovascular, non-CAD related
Non-cardiovascular related</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Rehospitalization</measure>
    <time_frame>4 years</time_frame>
    <description>CAD related
Cardiovascular, non-CAD related
Non-cardiovascular related</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Rehospitalization</measure>
    <time_frame>5 years</time_frame>
    <description>CAD related
Cardiovascular, non-CAD related
Non-cardiovascular related</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Repeat Coronary Arteriography</measure>
    <time_frame>In-hospital (≤ 7 days post index procedure)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Repeat Coronary Arteriography</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Repeat Coronary Arteriography</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Repeat Coronary Arteriography</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Repeat Coronary Arteriography</measure>
    <time_frame>270 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Repeat Coronary Arteriography</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Repeat Coronary Arteriography</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Repeat Coronary Arteriography</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Repeat Coronary Arteriography</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Repeat Coronary Arteriography</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Landmark Analysis on MACE and TVF and Their Components</measure>
    <time_frame>3-4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Landmark Analysis on MACE and TVF and Their Components</measure>
    <time_frame>3-5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Landmark Analysis on Scaffold Thrombosis/Stent Thrombosis (Per ARC Definition, Definite and Probable)</measure>
    <time_frame>3-4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Landmark Analysis on Scaffold Thrombosis/Stent Thrombosis (Per ARC Definition, Definite and Probable)</measure>
    <time_frame>3-5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Lesion Failure (TLF)</measure>
    <time_frame>1 year</time_frame>
    <description>The analysis will be based on 4610 subjects (2000 primary analysis subjects of ABSORB III and 2610 subjects of ABSORB IV)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Cumulative Stent/Scaffold Thrombosis</measure>
    <time_frame>0 to 30 Days</time_frame>
    <description>Stent thrombosis was defined by Academic Research Consortium (ARC) criteria as definite (angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic ECG changes that suggest acute ischemia or typical rise and fall of cardiac biomarkers OR pathological confirmation at autopsy or via examination of tissue retrieved following thrombectomy), probable (any unexplained death within the first 30 days or, regardless of the time after the index procedure, any Myocardial infarction (MI) related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation and in the absence of any other obvious cause), and possible (any unexplained death from 30 days after intracoronary stenting until end of trial follow-up). Stent thrombosis was categorized as acute (0-24 hours post stent implantation), Subacute (&gt;24 hours to 30 days post stent implantation), late (&gt;30 days to 1 year post stent implantation).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Patient Reported Outcomes</measure>
    <time_frame>Baseline</time_frame>
    <description>Patient-reported outcomes are informational endpoints to assess Health-Related Quality of Life. PRO assessments will be conducted at baseline, 1 and 6 months, and at 1, 3 and 5 years.
The following questionnaires will be used in this study:
Seattle Angina Questionnaire-7 (SAQ-7) to assess disease-specific Quality of Life
EuroQoL 5D (EQ-5D) survey to assess overall health status
(Note: PRO endpoints will be evaluated in the ~2610 subjects of ABSORB IV)
The PROs will be analyzed to evaluate the relationship between quality of life and cardiovascular events that occurred post-PCI and to substantiate the clinical impact of the angina events identified in the trial.
Assessments are made at all time points listed. But overall analysis of QoL is planned to be conducted at the end of the trial.</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient Reported Outcomes</measure>
    <time_frame>1 month</time_frame>
    <description>Patient-reported outcomes are informational endpoints to assess Health-Related Quality of Life. PRO assessments will be conducted at baseline, 1 and 6 months, and at 1, 3 and 5 years.
The following questionnaires will be used in this study:
Seattle Angina Questionnaire-7 (SAQ-7) to assess disease-specific Quality of Life
EuroQoL 5D (EQ-5D) survey to assess overall health status
(Note: PRO endpoints will be evaluated in the ~2610 subjects of ABSORB IV)
The PROs will be analyzed to evaluate the relationship between quality of life and cardiovascular events that occurred post-PCI and to substantiate the clinical impact of the angina events identified in the trial.
Assessments are made at all time points listed. But overall analysis of QoL is planned to be conducted at the end of the trial.</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient Reported Outcomes</measure>
    <time_frame>6 months</time_frame>
    <description>Patient-reported outcomes are informational endpoints to assess Health-Related Quality of Life. PRO assessments will be conducted at baseline, 1 and 6 months, and at 1, 3 and 5 years.
The following questionnaires will be used in this study:
Seattle Angina Questionnaire-7 (SAQ-7) to assess disease-specific Quality of Life
EuroQoL 5D (EQ-5D) survey to assess overall health status
(Note: PRO endpoints will be evaluated in the ~2610 subjects of ABSORB IV)
The PROs will be analyzed to evaluate the relationship between quality of life and cardiovascular events that occurred post-PCI and to substantiate the clinical impact of the angina events identified in the trial.
Assessments are made at all time points listed. But overall analysis of QoL is planned to be conducted at the end of the trial.</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient Reported Outcomes</measure>
    <time_frame>1 year</time_frame>
    <description>Patient-reported outcomes are informational endpoints to assess Health-Related Quality of Life. PRO assessments will be conducted at baseline, 1 and 6 months, and at 1, 3 and 5 years.
The following questionnaires will be used in this study:
Seattle Angina Questionnaire-7 (SAQ-7) to assess disease-specific Quality of Life
EuroQoL 5D (EQ-5D) survey to assess overall health status
(Note: PRO endpoints will be evaluated in the ~2610 subjects of ABSORB IV)
The PROs will be analyzed to evaluate the relationship between quality of life and cardiovascular events that occurred post-PCI and to substantiate the clinical impact of the angina events identified in the trial.
Assessments are made at all time points listed. But overall analysis of QoL is planned to be conducted at the end of the trial.</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient Reported Outcomes</measure>
    <time_frame>3 years</time_frame>
    <description>Patient-reported outcomes are informational endpoints to assess Health-Related Quality of Life. PRO assessments will be conducted at baseline, 1 and 6 months, and at 1, 3 and 5 years.
The following questionnaires will be used in this study:
Seattle Angina Questionnaire-7 (SAQ-7) to assess disease-specific Quality of Life
EuroQoL 5D (EQ-5D) survey to assess overall health status
(Note: PRO endpoints will be evaluated in the ~2610 subjects of ABSORB IV)
The PROs will be analyzed to evaluate the relationship between quality of life and cardiovascular events that occurred post-PCI and to substantiate the clinical impact of the angina events identified in the trial.
Assessments are made at all time points listed. But overall analysis of QoL is planned to be conducted at the end of the trial.</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient Reported Outcomes (PRO)</measure>
    <time_frame>5 years</time_frame>
    <description>Patient-reported outcomes (PRO) are informational endpoints to assess Health-Related Quality of Life. PRO assessments will be conducted at baseline, 1 and 6 months, and at 1, 3 and 5 years.
The following questionnaires will be used in this study:
Seattle Angina Questionnaire-7 (SAQ-7) to assess disease-specific Quality of Life
EuroQoL 5D (EQ-5D) survey to assess overall health status
(Note: PRO endpoints will be evaluated in the ~2610 subjects of ABSORB IV)
The PROs will be analyzed to evaluate the relationship between quality of life and cardiovascular events that occurred post-PCI and to substantiate the clinical impact of the angina events identified in the trial.
Assessments are made at all time points listed. But overall analysis of QoL is planned to be conducted at the end of the trial.</description>
  </other_outcome>
  <other_outcome>
    <measure>Landmark Analysis on TLF and Components</measure>
    <time_frame>3-4 years</time_frame>
    <description>TLF is defined as composite of Cardiac Death, Myocardial Infarction (MI) attributable to Target Vessel (TV-MI), or Ischemia- Driven Target Lesion Revascularization (ID-TLR).</description>
  </other_outcome>
  <other_outcome>
    <measure>Landmark Analysis on TLF and Components</measure>
    <time_frame>3-5 years</time_frame>
    <description>TLF is defined as composite of Cardiac Death, Myocardial Infarction (MI) attributable to Target Vessel (TV-MI), or Ischemia- Driven Target Lesion Revascularization (ID-TLR).</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2610</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Coronary Artery Stenosis</condition>
  <condition>Coronary Disease</condition>
  <condition>Coronary Stenosis</condition>
  <arm_group>
    <arm_group_label>Absorb BVS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
  </arm_group>
  <arm_group>
    <arm_group_label>XIENCE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) and XIENCE ProX (outside of the US only)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Absorb BVS</intervention_name>
    <description>Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
Once Absorb GT1™ BVS System is commercially available, it can also be used in the ABSORB IV trial. Scaffold diameters: 2.5, 3.0 and 3.5 mm of and scaffold lengths: 8, 12, 18, 23, and 28 mm.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
    <arm_group_label>Absorb BVS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>XIENCE</intervention_name>
    <description>Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm. The 3.25 mm is only available for XIENCE Xpedition
Stent lengths: 8, 12, 15, 18, 23, and 28 mm
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
    <arm_group_label>XIENCE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        General Inclusion Criteria:

          1. Subject must be at least 18 years of age.

          2. Subject or a legally authorized representative must provide written Informed Consent
             prior to any study related procedure, per site requirements.

          3. Subject must have evidence of myocardial ischemia (e.g., silent ischemia, stable or
             unstable angina, non-ST-segment elevation MI (NSTEMI), OR recent ST-segment elevation
             MI (STEMI). Patients with stable coronary syndromes can be enrolled any time after
             symptom onset if eligibility criteria are otherwise met. Patients with acute coronary
             syndrome can be enrolled under the following conditions:

               1. Unstable angina or NSTEMI within 2 weeks of the index procedure.

               2. STEMI &gt; 72 hours ≤ 2 weeks prior to the index procedure.

             Note: Subjects with Unstable angina (UA) or NSTEMI or STEMI occurring &gt; 2 weeks of the
             index procedure can be included in the trial but should be categorized based on their
             current angina class.

          4. Subjects must be suitable for PCI. Subjects with stable angina or silent ischemia and
             &lt; 70% diameter stenosis must have objective signs of ischemia as determined by one of
             the following: abnormal stress echocardiogram, nuclear scan, electrocardiogram (ECG),
             positron emission tomography (PET), magnetic resonance imaging (MRI), and/or
             fractional flow reserve (FFR).

             (Note: subject with silent ischemia must have a prior history of typical angina,
             angina-equivalent symptoms, or atypical angina within the past year to be included in
             the trial.)

          5. Subject must be an acceptable candidate for coronary artery bypass graft (CABG)
             surgery.

          6. Female subject of childbearing potential who does not plan pregnancy for up to 1 year
             following the index procedure. For a female subject of childbearing potential a
             pregnancy test must be performed with negative results known within 7 days prior to
             the index procedure per site standard.

          7. Female subject is not breast-feeding at the time of the screening visit and will not
             be breast-feeding for at least 1 year following the index procedure.

          8. Subject agrees to not participate in any other investigational or invasive clinical
             study for a period of 5 years following the index procedure.

        Angiographic Inclusion Criteria:

        Treatment of up to three de novo lesions in a maximum of two epicardial vessels, with a
        maximum of two lesions per epicardial vessel. If only a single lesion is to be treated, it
        must be a target lesion. Up to one non-target lesion can be treated. Non-target lesion
        treatment can occur only in a non-target vessel.

        If there are two target lesions within the same epicardial vessel, the two target lesions
        must be at least 15 mm apart per visual estimation; otherwise this is considered as a
        single target lesion for lesion (and stent) length determination and must be treated with a
        single study device.

        1. Target lesion(s) must be located in a native coronary artery with a visually estimated
        or quantitatively assessed %DS of ≥50% and &lt; 100%, with a thrombolysis in myocardial
        infarction (TIMI) flow of ≥ 1, and one of the following: stenosis ≥ 70%, an abnormal
        functional test (e.g., fractional flow reserve ≤0.80 AND/OR a positive stress test), or
        presentation with an acute coronary syndrome (unstable angina or NSTEMI within 2 weeks of
        index procedure, or STEMI &gt;72 hours but ≤ 2 weeks prior to the index procedure).

          1. Target lesion(s) must be located in a native coronary artery with reference vessel
             diameter (RVD) by visual estimation of ≥ 2.50 mm and ≤ 3.75 mm.

          2. Target lesion(s) must be located in a native coronary artery with length by visual
             estimation of ≤ 24 mm.

        Note: Subjects with Unstable angina (UA) or NSTEMI or STEMI occurring &gt; 2 weeks of the
        index procedure can be included in the trial but should be categorized based on their
        current angina class.

        Note: To exclude enrollment of excessively small vessels, if the operator believes that
        based on visual angiographic assessments, the distal reference vessel diameter is ≤ 2.75 mm
        such that the plan is to implant a 2.5 mm device (stent or scaffold) in a target lesion, it
        is strongly recommended that either on-line QCA or intravascular imaging (ultrasound or
        optical coherence tomography) is used and demonstrates that the measured distal RVD for
        this target lesion is ≥ 2.50 mm (by at least one of these imaging modalities). This
        measurement may be performed before or after pre-dilatation, but before randomization. If
        the distal RVD measures &lt;2.5 mm, that lesion IS NOT ELIGIBLE for randomization. Such a
        lesion may be treated as a non-target lesion.

        General Exclusion Criteria:

          1. Any surgery requiring general anesthesia or discontinuation of aspirin and/or a P2Y12
             receptor inhibitor is planned within 12 months after the procedure.

          2. Subject has known hypersensitivity or contraindication to device material and its
             degradants (everolimus, poly (L-lactide), poly (DL-lactide), lactide, lactic acid) and
             cobalt, chromium, nickel, platinum, tungsten, acrylic and fluoro polymers that cannot
             be adequately pre-medicated. Subject has a known contrast sensitivity that cannot be
             adequately pre-medicated.

          3. Subject has known allergic reaction, hypersensitivity or contraindication to any of
             the following: aspirin; or clopidogrel and prasugrel and ticagrelor; or heparin and
             bivalirudin, and therefore cannot be adequately treated with study medications.

          4. Subject had an acute STEMI (appropriate clinical syndrome with ≥1 mm of ST-segment
             elevation in ≥2 contiguous leads) within 72 hours of the index procedure.

          5. Subject has a cardiac arrhythmia identified at the time of screening for which at
             least one of the following criteria is met:

               1. Subject requires coumadin or any other agent for chronic oral anticoagulation.

               2. Subject is likely to become hemodynamically unstable due to their arrhythmia.

               3. Subject has poor survival prognosis due to their arrhythmia.

          6. Subject has a left ventricular ejection fraction (LVEF) &lt; 30% assessed by any
             quantitative method, including but not limited to echocardiography, MRI,
             multiple-gated acquisition (MUGA) scan, contrast left ventriculography, PET scan, etc.
             LVEF may be obtained within 6 months prior to the procedure for subjects with stable
             CAD. For subjects presenting with acute coronary syndrome (ACS), LVEF must be assessed
             within 1 week of the index procedure and after ACS presentation, which may include
             contrast left ventriculography during the index procedure but prior to randomization
             in order to confirm the subject's eligibility.

          7. Subject has undergone prior PCI within the target vessel during the last 12 months.
             Prior PCI within the non-target vessel or any peripheral intervention is acceptable if
             performed anytime &gt;30 days before the index procedure, or between a minimum of 24
             hours and 30 days before the index procedure if successful and uncomplicated.

          8. Subject requires future staged PCI of any lesion other than a target lesion identified
             at the time of index procedure; or subject requires future peripheral vascular
             interventions &lt; 30 days after the index procedure.

          9. Subject has received any solid organ transplants or is on a waiting list for any solid
             organ transplants.

         10. At the time of screening, the subject has a malignancy that is not in remission.

         11. Subject is receiving immunosuppressant therapy or has known immunosuppressive or
             severe autoimmune disease that requires chronic immunosuppressive therapy (e.g., human
             immunodeficiency virus, systemic lupus erythematosus, etc.). Note: corticosteroids are
             not included as immunosuppressant therapy.

         12. Subject has previously received or is scheduled to receive radiotherapy to a coronary
             artery (vascular brachytherapy), or the chest/mediastinum.

         13. Subject is receiving or will require chronic anticoagulation therapy (e.g., coumadin,
             dabigatran, apixaban, rivaroxaban, edoxaban or any other related agent for any
             reason).

         14. Subject has a platelet count &lt; 100,000 cells/mm3 or &gt; 700,000 cells/mm3.

         15. Subject has a documented or suspected hepatic disorder as defined as cirrhosis or
             Child-Pugh ≥ Class B.

         16. Subject has renal insufficiency as defined as an estimated glomerular filtration rate
             (GFR) &lt; 30 ml/min/1.73m2 or dialysis at the time of screening.

         17. Subject is high risk of bleeding for any reason; has a history of bleeding diathesis
             or coagulopathy; has had a significant gastrointestinal or significant urinary bleed
             within the past six months.

         18. Subject has had a cerebrovascular accident or transient ischemic neurological attack
             (TIA) within the past six months, or any prior intracranial bleed, or any permanent
             neurologic defect, or any known intracranial pathology (e.g. aneurysm, arteriovenous
             malformation, etc.).

         19. Subject has extensive peripheral vascular disease that precludes safe 6 French sheath
             insertion. Note: femoral arterial disease does not exclude the patient if radial
             access may be used.

         20. Subject has a life expectancy &lt;5 years for any non-cardiac or cardiac cause.

         21. Subject is in the opinion of the Investigator or designee, unable to comply with the
             requirements of the study protocol or is unsuitable for the study for any reason. This
             includes completion of Patient Reported Outcome instruments.

         22. Subject is currently participating in another clinical trial that has not yet
             completed its primary endpoint.

         23. Subject is part of a vulnerable population who, in the judgment of the investigator,
             is unable to give Informed Consent for reasons of incapacity, immaturity, adverse
             personal circumstances or lack of autonomy. This may include: Individuals with a
             mental disability, persons in nursing homes, children, impoverished persons, persons
             in emergency situations, homeless persons, nomads, refugees, and those incapable of
             giving informed consent. Vulnerable populations also may include members of a group
             with a hierarchical structure such as university students, subordinate hospital and
             laboratory personnel, employees of the Sponsor, members of the armed forces, and
             persons kept in detention.

        Angiographic Exclusion Criteria:

        All exclusion criteria apply to the target lesion(s) or target vessel(s).

          1. Unsuccessful pre-dilatation, defined as the presence of one or more of the following
             (note: successful pre-dilatation of at least one target lesion is required prior to
             randomization):

               1. Residual %diameter stenosis (DS) after pre-dilatation is ≥ 40% (per visual
                  estimation). Note: achieving a %DS ≤ 20% prior to randomization is strongly
                  recommended.

               2. TIMI flow grade &lt;3 (per visual estimation).

               3. Any angiographic complication (e.g. distal embolization, side branch closure).

               4. Any dissection NHLBI grade D-F.

               5. Any chest pain lasting &gt; 5 minutes.

               6. Any ST-segment depression or elevation lasting &gt; 5 minutes.

          2. Lesion is located in left main or there is a ≥30% diameter stenosis in the left main
             (unless the left main lesion is a protected left main (i.e. a patent bypass graft to
             the LAD and/or LCX arteries is present), and there is no intention to treat the
             protected left main lesion).

          3. Aorto-ostial right coronary artery (RCA) lesion (within 3 mm of the ostium).

          4. Lesion located within 3 mm of the origin of the left anterior descending artery (LAD)
             or left circumflex artery (LCX).

          5. Lesion involving a bifurcation with a:

               1. side branch ≥ 2 mm in diameter, or

               2. side branch with either an ostial or non-ostial lesion with diameter stenosis
                  &gt;50%, or

               3. side branch requiring dilatation

          6. Anatomy proximal to or within the lesion that may impair delivery of the Absorb BVS or
             XIENCE stent:

               1. Extreme angulation (≥ 90°) proximal to or within the target lesion.

               2. Excessive tortuosity (≥ two 45° angles) proximal to or within the target lesion.

               3. Moderate or heavy calcification proximal to or within the target lesion. If
                  intravascular ultrasound (IVUS) used, subject must be excluded if calcium arc in
                  the vessel prior to the lesion or within the lesion is ≥ 180°.

          7. Lesion or vessel involves a myocardial bridge.

          8. Vessel has been previously treated with a stent and the target lesion is within 5 mm
             proximal or distal to a previously stented lesion.

          9. Target lesion located within an arterial or saphenous vein graft or distal to any
             arterial or saphenous vein graft.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregg W Stone, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Columbia University Medical Center, New York, NY</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gregg W Stone, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University Medical Center, New York, NY</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephen G Ellis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cleveland Clinic, Cleveland OH</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dean J Kereiakes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Christ Hospital, Cincinnati, OH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chandler Regional Medical Center</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Gilbert Medical Center</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85297</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Banner Heart Hospital</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scottsdale Healthcare</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arkansas Heart Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Muir Medical Center</name>
      <address>
        <city>Concord</city>
        <state>California</state>
        <zip>94520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Hospital</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scripps Memorial Hospital, La Jolla</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Good Samaritan Hospital</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ronald Regean UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90066</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sutter Memorial Hospital</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95819</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sharp Memorial Hospital</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Hospital and Clinics</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Little Company Of Mary Hospital</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Torrance Memorial Medical Center</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center of the Rockies</name>
      <address>
        <city>Loveland</city>
        <state>Colorado</state>
        <zip>80538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale-New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morton Plant Hospital</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holy Cross Hospital</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Regional Hospital</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincents Medical Center</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Medical Center - Downtown</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida - Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Hospital of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palm Beach Gardens Medical Center</name>
      <address>
        <city>Palm Beach Gardens</city>
        <state>Florida</state>
        <zip>33410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Hospital West</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tallahassee Memorial Hospital</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampa General Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Midtown</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont Hospital Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northeast Georgia Medical Center</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <zip>30501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advocate Christ Medical Center</name>
      <address>
        <city>Oak Lawn</city>
        <state>Illinois</state>
        <zip>60453</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. John's Hospital</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62769</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elkhart General Hospital</name>
      <address>
        <city>Elkhart</city>
        <state>Indiana</state>
        <zip>46514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Francisan St. Francis Health</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Vincent Heart Center of Indiana</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Baptist Hospital</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jewish Hospital</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Hospital East Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Maine Medical Center</name>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <zip>04401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Union Memorial Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Hospital Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02241-8203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMass Memorial Medical Center</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Mercy Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48197</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bay Regional Medical Center</name>
      <address>
        <city>Bay City</city>
        <state>Michigan</state>
        <zip>48706</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oakwood Hospital</name>
      <address>
        <city>Dearborn</city>
        <state>Michigan</state>
        <zip>48124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harper University Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. John's Hospital and Medical Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Michigan Hospital</name>
      <address>
        <city>Petoskey</city>
        <state>Michigan</state>
        <zip>49770</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beaumont Hospitals</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Mississippi Medical Center</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boone Hospital Center</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barnes Jewish Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital - Springfield</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Patrick Hospital</name>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <zip>59802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nebraska Heart Hospital</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alegent Bergant - Omaha</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Memorial Hospital</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cooper University Hospital</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Our Lady of Lourdes Medical Center</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Englewood Hospital and Medical Center</name>
      <address>
        <city>Englewood</city>
        <state>New Jersey</state>
        <zip>07631</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morristown Memorial MED CTR</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jersey Shore University Medical Center</name>
      <address>
        <city>Neptune</city>
        <state>New Jersey</state>
        <zip>07754</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queens Hospital</name>
      <address>
        <city>Flushing</city>
        <state>New York</state>
        <zip>11355</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian Hospital-Cornell</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rochester General Hospital</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Strong Memorial Hospital</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stony Brook Hospital and Medical Center</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Hospital Health Center</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center- North East</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presbyterian Hospital</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center-Pineville</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rex Hospital</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Med</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aultman Hospital</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Christ Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy St. Vincent Medical Center</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Genesis Good Samaritan Hospital</name>
      <address>
        <city>Zanesville</city>
        <state>Ohio</state>
        <zip>43701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Integris Baptist Medical Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence St. Vincent Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sacred Heart Medical Center</name>
      <address>
        <city>Springfield</city>
        <state>Oregon</state>
        <zip>97477</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bryn Mawr</name>
      <address>
        <city>Bryn Mawr</city>
        <state>Pennsylvania</state>
        <zip>19010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holy Spirit Hospital</name>
      <address>
        <city>Camp Hill</city>
        <state>Pennsylvania</state>
        <zip>17011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geisinger Medical Center</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Doylestown Hospital</name>
      <address>
        <city>Doylestown</city>
        <state>Pennsylvania</state>
        <zip>18901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pinnacle Health at Harrisburg Hospital</name>
      <address>
        <city>Harrisburg</city>
        <state>Pennsylvania</state>
        <zip>17105-8700</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Shore Hospital</name>
      <address>
        <city>Harrisburg</city>
        <state>Pennsylvania</state>
        <zip>17110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn Presbyterian Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alleghany General Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Medical Center</name>
      <address>
        <city>Reading</city>
        <state>Pennsylvania</state>
        <zip>19605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Miriam Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anmed Health</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Hospital</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenville Memorial Hospital</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanford USD Medical Center</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Hospital</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wellmont Holston Valley Medical Center</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Texas Healthcare System</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seton Medical Center Austin</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Heart and Vascular Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harrison Methodist</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Episcopal Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Texas Medical Center</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carilion Roanoke Memorial Hospital</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winchester Medical Center</name>
      <address>
        <city>Winchester</city>
        <state>Virginia</state>
        <zip>22601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Everett Med Ctr</name>
      <address>
        <city>Everett</city>
        <state>Washington</state>
        <zip>98201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liverpool Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <zip>2170</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Public Hospital</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Prince Charles Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4032</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane Womens</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Hospital Melbourne</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Epworth Healthcare Hospital</name>
      <address>
        <city>Richmond</city>
        <state>Victoria</state>
        <zip>3121</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fiona Stanley Hospital</name>
      <address>
        <city>Murdoch</city>
        <state>Western Australia</state>
        <zip>6150</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Perth Hospital</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6001</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Heart Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Université de Montréal (CHUM)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1T8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital du Sacre-Coeur de Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4J 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-Württemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ulm</name>
      <address>
        <city>Ulm</city>
        <state>Baden-Württemberg</state>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken Oberallgau gGmbH</name>
      <address>
        <city>Immenstadt</city>
        <state>Bavaria</state>
        <zip>87509</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Kempten, Klinikverbund Keptem-Oberallgae</name>
      <address>
        <city>Kempten-Allgau</city>
        <state>Bavaria</state>
        <zip>87439</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Immanuel Klinikum Bernau Herzzentrum Brandenburg</name>
      <address>
        <city>Bernau</city>
        <state>Berlin</state>
        <zip>16321</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Giessen</name>
      <address>
        <city>Giessen</city>
        <state>Hesse</state>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oldenburg</name>
      <address>
        <city>Oldenburg</city>
        <state>Lower Saxony</state>
        <zip>26133</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <state>North Rhine-Westphalia</state>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elisabeth-Krankenhaus Essen</name>
      <address>
        <city>Essen</city>
        <state>North Rhine-Westphalia</state>
        <zip>45138</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mainz</name>
      <address>
        <city>Mainz</city>
        <state>Rhineland-Palatinate</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Segeberger Kliniken GmbH</name>
      <address>
        <city>Bad Segeberg</city>
        <state>Schleswig-Holstein</state>
        <zip>23795</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>June 9, 2014</study_first_submitted>
  <study_first_submitted_qc>June 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2014</study_first_posted>
  <results_first_submitted>April 20, 2018</results_first_submitted>
  <results_first_submitted_qc>June 27, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">July 24, 2018</results_first_posted>
  <last_update_submitted>November 4, 2019</last_update_submitted>
  <last_update_submitted_qc>November 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Absorb™ BVS</keyword>
  <keyword>Angioplasty</keyword>
  <keyword>Bioabsorbable</keyword>
  <keyword>BVS</keyword>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Coronary Artery Endothelial Responsiveness</keyword>
  <keyword>Coronary artery restenosis</keyword>
  <keyword>Coronary artery stenosis</keyword>
  <keyword>Coronary scaffold</keyword>
  <keyword>Coronary Stent</keyword>
  <keyword>Drug eluting stents</keyword>
  <keyword>Everolimus</keyword>
  <keyword>Myocardial ischemia</keyword>
  <keyword>Stent thrombosis</keyword>
  <keyword>Stents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 16, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/79/NCT02173379/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 16, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/79/NCT02173379/Prot_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 2610 subjects were originally randomized at 147 sites between August 15, 2014 and March 31, 2017. The last 30-day follow-up visit occurred on April 27, 2017. The database was then cleaned and locked, and data extraction for the 30-day analysis occurred on August 21, 2017.</recruitment_details>
      <pre_assignment_details>In preparation for database lock for the primary endpoint analysis, a review of the database was conducted that identified 6 patients that were randomized in error. None of these patients received a study device, and they were all withdrawn by physician.Therefore, the analyzable population is 2604.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Absorb BVS</title>
          <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS), and the Absorb GT1™ BVS System</description>
        </group>
        <group group_id="P2">
          <title>XIENCE</title>
          <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1296"/>
                <participants group_id="P2" count="1308"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1287"/>
                <participants group_id="P2" count="1301"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawn by the physician</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Absorb BVS</title>
          <description>Subjects receiving public) Absorb Bioresorbable Vascular Scaffold (BVS), and the Absorb GT1™ BVS System</description>
        </group>
        <group group_id="B2">
          <title>XIENCE</title>
          <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1296"/>
            <count group_id="B2" value="1308"/>
            <count group_id="B3" value="2604"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.1" spread="10.1"/>
                    <measurement group_id="B2" value="62.2" spread="10.3"/>
                    <measurement group_id="B3" value="62.65" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="369"/>
                    <measurement group_id="B2" value="361"/>
                    <measurement group_id="B3" value="730"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="927"/>
                    <measurement group_id="B2" value="947"/>
                    <measurement group_id="B3" value="1874"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="69"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1256"/>
                    <measurement group_id="B2" value="1279"/>
                    <measurement group_id="B3" value="2535"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="132"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1135"/>
                    <measurement group_id="B2" value="1160"/>
                    <measurement group_id="B3" value="2295"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1021"/>
                    <measurement group_id="B2" value="1041"/>
                    <measurement group_id="B3" value="2062"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="164"/>
                    <measurement group_id="B2" value="171"/>
                    <measurement group_id="B3" value="335"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Singapore</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Target Lesion Failure (TLF)</title>
        <description>Target lesion failure (TLF) composite of Cardiac Death, Myocardial Infarction attributable to Target Vessel (TV-MI), or Ischemia-Driven Target Lesion Revascularization (ID-TLR))</description>
        <time_frame>30 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Lesion Failure (TLF)</title>
          <description>Target lesion failure (TLF) composite of Cardiac Death, Myocardial Infarction attributable to Target Vessel (TV-MI), or Ischemia-Driven Target Lesion Revascularization (ID-TLR))</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1288"/>
                <count group_id="O2" value="1303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The hypothesis test is designed to show non-inferiority of Absorb BVS to XIENCE for the primary endpoint with a one-sided alpha of 0.025. The null (H0) and alternative (HA) hypotheses are:
H0: TLFAbsorb - TLFXIENCE ≥ ∆TLF HA: TLFAbsorb - TLFXIENCE &lt; ∆TLF.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>One-sided p-value by using Farrington-Manning non-inferiority test statistic with non-inferiority margin of 2.9%, to be compared with a one-sided significance level of 0.025.</non_inferiority_desc>
            <p_value>0.0244</p_value>
            <method>Farrington-Manning</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Powered TLF, Tested for Non-inferiority of Absorb BVS to XIENCE</title>
        <description>This analysis will consist of ~2610 subjects in ABSORB IV.</description>
        <time_frame>1 year</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Powered Angina</title>
        <description>Angina is defined as any angina or angina equivalent symptoms determined by the physician and/or research coordinator after interview of the patient, and as adjudicated by a clinical events committee (CEC).
This analysis will exclude angina or angina equivalent symptoms that occurred following the index procedure through hospital discharge or 7 days, whichever occurs first.</description>
        <time_frame>30 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Powered Angina</title>
          <description>Angina is defined as any angina or angina equivalent symptoms determined by the physician and/or research coordinator after interview of the patient, and as adjudicated by a clinical events committee (CEC).
This analysis will exclude angina or angina equivalent symptoms that occurred following the index procedure through hospital discharge or 7 days, whichever occurs first.</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1287"/>
                <count group_id="O2" value="1301"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117"/>
                    <measurement group_id="O2" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Target Lesion With Acute Success- Device Success (Lesion Level Analysis)</title>
        <description>Successful delivery and deployment of the study scaffold/stent at the intended target lesion and successful withdrawal of the delivery system with attainment of final in-scaffold/stent residual stenosis of less than 30% by quantitative coronary angiography (QCA) (by visual estimation if QCA unavailable). When bailout scaffold/stent is used, the success or failure of the bailout scaffold/stent delivery and deployment is not one of the criteria for device success.</description>
        <time_frame>In-hospital (≤ 7days)</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Target Lesion With Acute Success- Device Success (Lesion Level Analysis)</title>
          <description>Successful delivery and deployment of the study scaffold/stent at the intended target lesion and successful withdrawal of the delivery system with attainment of final in-scaffold/stent residual stenosis of less than 30% by quantitative coronary angiography (QCA) (by visual estimation if QCA unavailable). When bailout scaffold/stent is used, the success or failure of the bailout scaffold/stent delivery and deployment is not one of the criteria for device success.</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Percentage of target lesions</units>
          <param>Number</param>
          <units_analyzed>Target lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1282"/>
                <count group_id="O2" value="1303"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Target lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1424"/>
                <count group_id="O2" value="1450"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.6"/>
                    <measurement group_id="O2" value="99.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Acute Success- Procedural Success (Subject Level Analysis)</title>
        <description>Achievement of final in-scaffold/stent residual stenosis of less than 30% by QCA (by visual estimation if QCA unavailable) with successful delivery and deployment of at least one study scaffold/stent at the intended target lesion and successful withdrawal of the delivery system for all target lesions without the occurrence of cardiac death, target vessel MI or repeat TLR during the hospital stay (maximum of 7 days).</description>
        <time_frame>In-hospital (≤ 7days)</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Acute Success- Procedural Success (Subject Level Analysis)</title>
          <description>Achievement of final in-scaffold/stent residual stenosis of less than 30% by QCA (by visual estimation if QCA unavailable) with successful delivery and deployment of at least one study scaffold/stent at the intended target lesion and successful withdrawal of the delivery system for all target lesions without the occurrence of cardiac death, target vessel MI or repeat TLR during the hospital stay (maximum of 7 days).</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1282"/>
                <count group_id="O2" value="1303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1203"/>
                    <measurement group_id="O2" value="1250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Death (Cardiac, Vascular, Non-cardiovascular)</title>
        <description>Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
        <time_frame>In-hospital (≤ 7 days post index procedure)</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Death (Cardiac, Vascular, Non-cardiovascular)</title>
          <description>Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1291"/>
                <count group_id="O2" value="1304"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Death (Cardiac, Vascular, Non-cardiovascular)</title>
        <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
        <time_frame>30 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Death (Cardiac, Vascular, Non-cardiovascular)</title>
          <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1288"/>
                <count group_id="O2" value="1303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Death (Cardiac, Vascular, Non-cardiovascular)</title>
        <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
        <time_frame>90 days</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Death (Cardiac, Vascular, Non-cardiovascular)</title>
        <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
        <time_frame>180 days</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Death (Cardiac, Vascular, Non-cardiovascular)</title>
        <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
        <time_frame>270 days</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Death (Cardiac, Vascular, Non-cardiovascular)</title>
        <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
        <time_frame>1 year</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Death (Cardiac, Vascular, Non-cardiovascular)</title>
        <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
        <time_frame>2 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Death (Cardiac, Vascular, Non-cardiovascular)</title>
        <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
        <time_frame>3 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Death (Cardiac, Vascular, Non-cardiovascular)</title>
        <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
        <time_frame>4 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Death (Cardiac, Vascular, Non-cardiovascular)</title>
        <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
        <time_frame>5 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Myocardial Infarction (MI)</title>
        <description>Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)</description>
        <time_frame>In-hospital (≤ 7 days post index procedure)</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Myocardial Infarction (MI)</title>
          <description>Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1291"/>
                <count group_id="O2" value="1304"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Myocardial Infarction (MI)</title>
        <description>Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)</description>
        <time_frame>30 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Myocardial Infarction (MI)</title>
          <description>Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1288"/>
                <count group_id="O2" value="1303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Myocardial Infarction (MI)</title>
        <description>Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)</description>
        <time_frame>90 days</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Myocardial Infarction (MI)</title>
        <description>Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)</description>
        <time_frame>180 days</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Myocardial Infarction (MI)</title>
        <description>Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)</description>
        <time_frame>270 days</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Myocardial Infarction (MI)</title>
        <description>Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)</description>
        <time_frame>1 year</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Myocardial Infarction (MI)</title>
        <description>Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)</description>
        <time_frame>2 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Myocardial Infarction (MI)</title>
        <description>Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)</description>
        <time_frame>3 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Myocardial Infarction (MI)</title>
        <description>Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)</description>
        <time_frame>4 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Myocardial Infarction (MI)</title>
        <description>Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)</description>
        <time_frame>5 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Lesion Revascularization (TLR)</title>
        <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</description>
        <time_frame>In-hospital (≤ 7 days post index procedure)</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Lesion Revascularization (TLR)</title>
          <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1291"/>
                <count group_id="O2" value="1304"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Lesion Revascularization (TLR)</title>
        <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</description>
        <time_frame>30 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Lesion Revascularization (TLR)</title>
          <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1288"/>
                <count group_id="O2" value="1303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants withTarget Lesion Revascularization (TLR)</title>
        <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</description>
        <time_frame>90 days</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Lesion Revascularization (TLR)</title>
        <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</description>
        <time_frame>180 days</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Lesion Revascularization (TLR)</title>
        <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</description>
        <time_frame>270 days</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Lesion Revascularization (TLR)</title>
        <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</description>
        <time_frame>1 year</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Lesion Revascularization (TLR)</title>
        <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</description>
        <time_frame>2 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Lesion Revascularization (TLR)</title>
        <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</description>
        <time_frame>3 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Lesion Revascularization (TLR)</title>
        <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</description>
        <time_frame>4 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Lesion Revascularization (TLR)</title>
        <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</description>
        <time_frame>5 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Revascularization (TVR)</title>
        <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.
TVR includes all TVR, excluding TLR</description>
        <time_frame>In-hospital (≤ 7 days post index procedure)</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Vessel Revascularization (TVR)</title>
          <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.
TVR includes all TVR, excluding TLR</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1291"/>
                <count group_id="O2" value="1304"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Revascularization (TVR)</title>
        <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.
TVR includes all TVR, excluding TLR</description>
        <time_frame>30 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Vessel Revascularization (TVR)</title>
          <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.
TVR includes all TVR, excluding TLR</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1288"/>
                <count group_id="O2" value="1303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Revascularization (TVR)</title>
        <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.
TVR includes all TVR, excluding TLR</description>
        <time_frame>90 days</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Revascularization (TVR)</title>
        <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. classified as: Ischemic driven TVR and Non-ischemic driven TVR.
-TVR includes all TVR, excluding TLR</description>
        <time_frame>180 days</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Revascularization (TVR)</title>
        <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.
TVR includes all TVR, excluding TLR</description>
        <time_frame>270 days</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Revascularization (TVR)</title>
        <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.
TVR includes all TVR, excluding TLR</description>
        <time_frame>1 year</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Revascularization (TVR)</title>
        <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.
TVR includes all TVR, excluding TLR</description>
        <time_frame>2 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Revascularization (TVR)</title>
        <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.
TVR includes all TVR, excluding TLR</description>
        <time_frame>3 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Revascularization (TVR)</title>
        <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.
TVR includes all TVR, excluding TLR</description>
        <time_frame>4 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Revascularization (TVR)</title>
        <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.
TVR includes all TVR, excluding TLR</description>
        <time_frame>5 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Coronary Revascularization</title>
        <description>Revascularization includes TLR, TVR excluding TLR, and non TVR.</description>
        <time_frame>In-hospital (≤ 7 days post index procedure)</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Coronary Revascularization</title>
          <description>Revascularization includes TLR, TVR excluding TLR, and non TVR.</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1291"/>
                <count group_id="O2" value="1304"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Coronary Revascularization</title>
        <description>Revascularization includes TLR, TVR excluding TLR, and non TVR.</description>
        <time_frame>30 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Coronary Revascularization</title>
          <description>Revascularization includes TLR, TVR excluding TLR, and non TVR.</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1288"/>
                <count group_id="O2" value="1303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Coronary Revascularization</title>
        <description>Revascularization includes TLR, TVR excluding TLR, and non TVR.</description>
        <time_frame>90 days</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Coronary Revascularization</title>
        <description>Revascularization includes TLR, TVR excluding TLR, and non TVR.</description>
        <time_frame>180 days</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Coronary Revascularization</title>
        <description>Revascularization includes TLR, TVR excluding TLR, and non TVR.</description>
        <time_frame>270 days</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Coronary Revascularization</title>
        <description>Revascularization includes TLR, TVR excluding TLR, and non TVR.</description>
        <time_frame>1 year</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Coronary Revascularization</title>
        <description>Revascularization includes TLR, TVR excluding TLR, and non TVR.</description>
        <time_frame>2 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Coronary Revascularization</title>
        <description>Revascularization includes TLR, TVR excluding TLR, and non TVR.</description>
        <time_frame>3 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Coronary Revascularization</title>
        <description>Revascularization includes TLR, TVR excluding TLR, and non TVR.</description>
        <time_frame>4 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Coronary Revascularization</title>
        <description>Revascularization includes TLR, TVR excluding TLR, and non TVR.</description>
        <time_frame>5 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced All Death/All MI</title>
        <description>All deaths includes
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
        <time_frame>In-hospital (≤ 7 days post index procedure)</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced All Death/All MI</title>
          <description>All deaths includes
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1291"/>
                <count group_id="O2" value="1304"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced All Death/All MI</title>
        <description>All deaths includes
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
        <time_frame>30 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced All Death/All MI</title>
          <description>All deaths includes
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1288"/>
                <count group_id="O2" value="1303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Death/All MI</title>
        <description>All deaths includes
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
        <time_frame>90 days</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Death/All MI</title>
        <description>All deaths includes
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
        <time_frame>180 days</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Death/All MI</title>
        <description>All deaths includes
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
        <time_frame>270 days</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Death/All MI</title>
        <description>All deaths includes
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
        <time_frame>1 year</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Death/All MI</title>
        <description>All deaths includes
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
        <time_frame>2 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Death/All MI</title>
        <description>All deaths includes
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
        <time_frame>3 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Death/All MI</title>
        <description>All deaths includes
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
        <time_frame>4 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Death/All MI</title>
        <description>All deaths includes
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
        <time_frame>5 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI</title>
        <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</description>
        <time_frame>In-hospital (≤ 7 days post index procedure)</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Cardiac Death/All MI</title>
          <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1291"/>
                <count group_id="O2" value="1304"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI</title>
        <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</description>
        <time_frame>30 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Cardiac Death/All MI</title>
          <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1288"/>
                <count group_id="O2" value="1303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI</title>
        <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</description>
        <time_frame>90 days</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI</title>
        <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</description>
        <time_frame>180 days</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI</title>
        <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</description>
        <time_frame>270 days</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI</title>
        <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</description>
        <time_frame>1 year</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI</title>
        <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</description>
        <time_frame>2 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI</title>
        <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</description>
        <time_frame>3 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI</title>
        <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</description>
        <time_frame>4 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI</title>
        <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</description>
        <time_frame>5 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)</title>
        <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
        <time_frame>In-hospital (≤ 7 days post index procedure)</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)</title>
          <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1291"/>
                <count group_id="O2" value="1304"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)</title>
        <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
        <time_frame>90 days</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)</title>
        <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
        <time_frame>180 days</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)</title>
        <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
        <time_frame>270 days</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)</title>
        <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
        <time_frame>1 year</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)</title>
        <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
        <time_frame>2 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)</title>
        <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
        <time_frame>3 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)</title>
        <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
        <time_frame>4 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)</title>
        <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
        <time_frame>5 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI/ID-TLR (Major Adverse Cardiac Events-MACE)</title>
        <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
        <time_frame>In-hospital (≤ 7 days post index procedure)</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Cardiac Death/All MI/ID-TLR (Major Adverse Cardiac Events-MACE)</title>
          <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1291"/>
                <count group_id="O2" value="1304"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced With Cardiac Death/All MI/ID-TLR (MACE)</title>
        <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
        <time_frame>30 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced With Cardiac Death/All MI/ID-TLR (MACE)</title>
          <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1288"/>
                <count group_id="O2" value="1303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)</title>
        <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
        <time_frame>90 days</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)</title>
        <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
        <time_frame>180 days</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)</title>
        <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
        <time_frame>270 days</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)</title>
        <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
        <time_frame>1 year</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)</title>
        <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
        <time_frame>2 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)</title>
        <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
        <time_frame>3 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)</title>
        <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
        <time_frame>4 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)</title>
        <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
        <time_frame>5 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (Target Vessel Failure, TVF)</title>
        <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
        <time_frame>In-hospital (≤ 7 days post index procedure)</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (Target Vessel Failure, TVF)</title>
          <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1291"/>
                <count group_id="O2" value="1304"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)</title>
        <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
        <time_frame>30 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)</title>
          <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1288"/>
                <count group_id="O2" value="1303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)</title>
        <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
        <time_frame>90 days</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)</title>
        <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
        <time_frame>180 days</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)</title>
        <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
        <time_frame>270 days</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)</title>
        <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
        <time_frame>1 year</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)</title>
        <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
        <time_frame>2 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)</title>
        <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
        <time_frame>3 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)</title>
        <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
        <time_frame>4 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)</title>
        <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
        <time_frame>5 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Death/All MI/All Revascularization (DMR)</title>
        <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.</description>
        <time_frame>In-hospital (≤ 7 days post index procedure)</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Death/All MI/All Revascularization (DMR)</title>
          <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1291"/>
                <count group_id="O2" value="1304"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Death/All MI/All Revascularization</title>
        <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.</description>
        <time_frame>30 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Death/All MI/All Revascularization</title>
          <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1288"/>
                <count group_id="O2" value="1303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Death/All MI/All Revascularization</title>
        <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.</description>
        <time_frame>90 days</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Death/All MI/All Revascularization</title>
        <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.</description>
        <time_frame>180 days</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Death/All MI/All Revascularization</title>
        <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.</description>
        <time_frame>270 days</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Death/All MI/All Revascularization</title>
        <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.</description>
        <time_frame>1 year</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Death/All MI/All Revascularization</title>
        <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.</description>
        <time_frame>2 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Death/All MI/All Revascularization</title>
        <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.</description>
        <time_frame>3 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Death/All MI/All Revascularization</title>
        <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.</description>
        <time_frame>4 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Death/All MI/All Revascularization</title>
        <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.</description>
        <time_frame>5 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Scaffold/Stent Thrombosis (Per Academic Research Consortium (ARC) Definition)</title>
        <description>Stent thrombosis was defined by Academic Research Consortium (ARC) criteria as definite (angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic ECG changes that suggest acute ischemia or typical rise and fall of cardiac biomarkers OR pathological confirmation at autopsy or via examination of tissue retrieved following thrombectomy), probable (any unexplained death within the first 30 days or, regardless of the time after the index procedure, any Myocardial infarction (MI) related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation and in the absence of any other obvious cause), and possible (any unexplained death from 30 days after intracoronary stenting until end of trial follow-up). Stent thrombosis was categorized as acute (0-24 hours post stent implantation), Subacute (&gt;24 hours to 30 days post stent implantation), late (&gt;30 days to 1 year post stent implantation).</description>
        <time_frame>Acute (0 - 24 hours post stent implantation)</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Scaffold/Stent Thrombosis (Per Academic Research Consortium (ARC) Definition)</title>
          <description>Stent thrombosis was defined by Academic Research Consortium (ARC) criteria as definite (angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic ECG changes that suggest acute ischemia or typical rise and fall of cardiac biomarkers OR pathological confirmation at autopsy or via examination of tissue retrieved following thrombectomy), probable (any unexplained death within the first 30 days or, regardless of the time after the index procedure, any Myocardial infarction (MI) related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation and in the absence of any other obvious cause), and possible (any unexplained death from 30 days after intracoronary stenting until end of trial follow-up). Stent thrombosis was categorized as acute (0-24 hours post stent implantation), Subacute (&gt;24 hours to 30 days post stent implantation), late (&gt;30 days to 1 year post stent implantation).</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1291"/>
                <count group_id="O2" value="1305"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Definite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Definite/Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Scaffold/Stent Thrombosis (Per ARC Definition)</title>
        <description>Stent thrombosis was defined by Academic Research Consortium (ARC) criteria as definite (angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic ECG changes that suggest acute ischemia or typical rise and fall of cardiac biomarkers OR pathological confirmation at autopsy or via examination of tissue retrieved following thrombectomy), probable (any unexplained death within the first 30 days or, regardless of the time after the index procedure, any Myocardial infarction (MI) related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation and in the absence of any other obvious cause), and possible (any unexplained death from 30 days after intracoronary stenting until end of trial follow-up). Stent thrombosis was categorized as acute (0-24 hours post stent implantation), Subacute (&gt;24 hours to 30 days post stent implantation), late (&gt;30 days to 1 year post stent implantation).</description>
        <time_frame>Subacute (&gt;24 hours - 30 days post stent implantation)</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Scaffold/Stent Thrombosis (Per ARC Definition)</title>
          <description>Stent thrombosis was defined by Academic Research Consortium (ARC) criteria as definite (angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic ECG changes that suggest acute ischemia or typical rise and fall of cardiac biomarkers OR pathological confirmation at autopsy or via examination of tissue retrieved following thrombectomy), probable (any unexplained death within the first 30 days or, regardless of the time after the index procedure, any Myocardial infarction (MI) related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation and in the absence of any other obvious cause), and possible (any unexplained death from 30 days after intracoronary stenting until end of trial follow-up). Stent thrombosis was categorized as acute (0-24 hours post stent implantation), Subacute (&gt;24 hours to 30 days post stent implantation), late (&gt;30 days to 1 year post stent implantation).</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1287"/>
                <count group_id="O2" value="1301"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Definite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Definite/Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Scaffold/Stent Thrombosis (Per ARC Definition)</title>
        <description>Stent thrombosis was defined by Academic Research Consortium (ARC) criteria as definite (angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic ECG changes that suggest acute ischemia or typical rise and fall of cardiac biomarkers OR pathological confirmation at autopsy or via examination of tissue retrieved following thrombectomy), probable (any unexplained death within the first 30 days or, regardless of the time after the index procedure, any Myocardial infarction (MI) related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation and in the absence of any other obvious cause), and possible (any unexplained death from 30 days after intracoronary stenting until end of trial follow-up). Stent thrombosis was categorized as acute (0-24 hours post stent implantation), Subacute (&gt;24 hours to 30 days post stent implantation), late (&gt;30 days to 1 year post stent implantation).</description>
        <time_frame>Late (30 days - 1 year post stent implantation)</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Scaffold/Stent Thrombosis (Per ARC Definition)</title>
        <description>Stent thrombosis was defined by Academic Research Consortium (ARC) criteria as definite (angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic ECG changes that suggest acute ischemia or typical rise and fall of cardiac biomarkers OR pathological confirmation at autopsy or via examination of tissue retrieved following thrombectomy), probable (any unexplained death within the first 30 days or, regardless of the time after the index procedure, any Myocardial infarction (MI) related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation and in the absence of any other obvious cause), and possible (any unexplained</description>
        <time_frame>Very late (&gt;1 year post stent implantation)</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Rehospitalization</title>
        <description>Coronary artery disease (CAD) related
Cardiovascular, non-CAD related
Non-cardiovascular related</description>
        <time_frame>30 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Rehospitalization</title>
          <description>Coronary artery disease (CAD) related
Cardiovascular, non-CAD related
Non-cardiovascular related</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1288"/>
                <count group_id="O2" value="1302"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Rehospitalization</title>
        <description>CAD related
Cardiovascular, non-CAD related
Non-cardiovascular related</description>
        <time_frame>90 days</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Rehospitalization</title>
        <description>CAD related
Cardiovascular, non-CAD related
Non-cardiovascular related</description>
        <time_frame>180 days</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Rehospitalization</title>
        <description>CAD related
Cardiovascular, non-CAD related
Non-cardiovascular related</description>
        <time_frame>270 days</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Rehospitalization</title>
        <description>CAD related
Cardiovascular, non-CAD related
Non-cardiovascular related</description>
        <time_frame>1 year</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Rehospitalization</title>
        <description>CAD related
Cardiovascular, non-CAD related
Non-cardiovascular related</description>
        <time_frame>2 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Rehospitalization</title>
        <description>CAD related
Cardiovascular, non-CAD related
Non-cardiovascular related</description>
        <time_frame>3 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Rehospitalization</title>
        <description>CAD related
Cardiovascular, non-CAD related
Non-cardiovascular related</description>
        <time_frame>4 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Rehospitalization</title>
        <description>CAD related
Cardiovascular, non-CAD related
Non-cardiovascular related</description>
        <time_frame>5 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Repeat Coronary Arteriography</title>
        <time_frame>In-hospital (≤ 7 days post index procedure)</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Repeat Coronary Arteriography</title>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1290"/>
                <count group_id="O2" value="1304"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Repeat Coronary Arteriography</title>
        <time_frame>30 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Repeat Coronary Arteriography</title>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1288"/>
                <count group_id="O2" value="1301"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Repeat Coronary Arteriography</title>
        <time_frame>90 days</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Repeat Coronary Arteriography</title>
        <time_frame>180 days</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Repeat Coronary Arteriography</title>
        <time_frame>270 days</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Repeat Coronary Arteriography</title>
        <time_frame>1 year</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Repeat Coronary Arteriography</title>
        <time_frame>2 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Repeat Coronary Arteriography</title>
        <time_frame>3 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Repeat Coronary Arteriography</title>
        <time_frame>4 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Repeat Coronary Arteriography</title>
        <time_frame>5 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Landmark Analysis on MACE and TVF and Their Components</title>
        <time_frame>3-4 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Landmark Analysis on MACE and TVF and Their Components</title>
        <time_frame>3-5 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Landmark Analysis on Scaffold Thrombosis/Stent Thrombosis (Per ARC Definition, Definite and Probable)</title>
        <time_frame>3-4 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Landmark Analysis on Scaffold Thrombosis/Stent Thrombosis (Per ARC Definition, Definite and Probable)</title>
        <time_frame>3-5 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Lesion Failure (TLF)</title>
        <description>The analysis will be based on 4610 subjects (2000 primary analysis subjects of ABSORB III and 2610 subjects of ABSORB IV)</description>
        <time_frame>1 year</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Cumulative Stent/Scaffold Thrombosis</title>
        <description>Stent thrombosis was defined by Academic Research Consortium (ARC) criteria as definite (angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic ECG changes that suggest acute ischemia or typical rise and fall of cardiac biomarkers OR pathological confirmation at autopsy or via examination of tissue retrieved following thrombectomy), probable (any unexplained death within the first 30 days or, regardless of the time after the index procedure, any Myocardial infarction (MI) related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation and in the absence of any other obvious cause), and possible (any unexplained death from 30 days after intracoronary stenting until end of trial follow-up). Stent thrombosis was categorized as acute (0-24 hours post stent implantation), Subacute (&gt;24 hours to 30 days post stent implantation), late (&gt;30 days to 1 year post stent implantation).</description>
        <time_frame>0 to 30 Days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS), and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cumulative Stent/Scaffold Thrombosis</title>
          <description>Stent thrombosis was defined by Academic Research Consortium (ARC) criteria as definite (angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic ECG changes that suggest acute ischemia or typical rise and fall of cardiac biomarkers OR pathological confirmation at autopsy or via examination of tissue retrieved following thrombectomy), probable (any unexplained death within the first 30 days or, regardless of the time after the index procedure, any Myocardial infarction (MI) related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation and in the absence of any other obvious cause), and possible (any unexplained death from 30 days after intracoronary stenting until end of trial follow-up). Stent thrombosis was categorized as acute (0-24 hours post stent implantation), Subacute (&gt;24 hours to 30 days post stent implantation), late (&gt;30 days to 1 year post stent implantation).</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1288"/>
                <count group_id="O2" value="1301"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Definite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Definite/Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Patient Reported Outcomes</title>
        <description>Patient-reported outcomes are informational endpoints to assess Health-Related Quality of Life. PRO assessments will be conducted at baseline, 1 and 6 months, and at 1, 3 and 5 years.
The following questionnaires will be used in this study:
Seattle Angina Questionnaire-7 (SAQ-7) to assess disease-specific Quality of Life
EuroQoL 5D (EQ-5D) survey to assess overall health status
(Note: PRO endpoints will be evaluated in the ~2610 subjects of ABSORB IV)
The PROs will be analyzed to evaluate the relationship between quality of life and cardiovascular events that occurred post-PCI and to substantiate the clinical impact of the angina events identified in the trial.
Assessments are made at all time points listed. But overall analysis of QoL is planned to be conducted at the end of the trial.</description>
        <time_frame>Baseline</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Patient Reported Outcomes</title>
        <description>Patient-reported outcomes are informational endpoints to assess Health-Related Quality of Life. PRO assessments will be conducted at baseline, 1 and 6 months, and at 1, 3 and 5 years.
The following questionnaires will be used in this study:
Seattle Angina Questionnaire-7 (SAQ-7) to assess disease-specific Quality of Life
EuroQoL 5D (EQ-5D) survey to assess overall health status
(Note: PRO endpoints will be evaluated in the ~2610 subjects of ABSORB IV)
The PROs will be analyzed to evaluate the relationship between quality of life and cardiovascular events that occurred post-PCI and to substantiate the clinical impact of the angina events identified in the trial.
Assessments are made at all time points listed. But overall analysis of QoL is planned to be conducted at the end of the trial.</description>
        <time_frame>1 month</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Patient Reported Outcomes</title>
        <description>Patient-reported outcomes are informational endpoints to assess Health-Related Quality of Life. PRO assessments will be conducted at baseline, 1 and 6 months, and at 1, 3 and 5 years.
The following questionnaires will be used in this study:
Seattle Angina Questionnaire-7 (SAQ-7) to assess disease-specific Quality of Life
EuroQoL 5D (EQ-5D) survey to assess overall health status
(Note: PRO endpoints will be evaluated in the ~2610 subjects of ABSORB IV)
The PROs will be analyzed to evaluate the relationship between quality of life and cardiovascular events that occurred post-PCI and to substantiate the clinical impact of the angina events identified in the trial.
Assessments are made at all time points listed. But overall analysis of QoL is planned to be conducted at the end of the trial.</description>
        <time_frame>6 months</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Patient Reported Outcomes</title>
        <description>Patient-reported outcomes are informational endpoints to assess Health-Related Quality of Life. PRO assessments will be conducted at baseline, 1 and 6 months, and at 1, 3 and 5 years.
The following questionnaires will be used in this study:
Seattle Angina Questionnaire-7 (SAQ-7) to assess disease-specific Quality of Life
EuroQoL 5D (EQ-5D) survey to assess overall health status
(Note: PRO endpoints will be evaluated in the ~2610 subjects of ABSORB IV)
The PROs will be analyzed to evaluate the relationship between quality of life and cardiovascular events that occurred post-PCI and to substantiate the clinical impact of the angina events identified in the trial.
Assessments are made at all time points listed. But overall analysis of QoL is planned to be conducted at the end of the trial.</description>
        <time_frame>1 year</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Patient Reported Outcomes</title>
        <description>Patient-reported outcomes are informational endpoints to assess Health-Related Quality of Life. PRO assessments will be conducted at baseline, 1 and 6 months, and at 1, 3 and 5 years.
The following questionnaires will be used in this study:
Seattle Angina Questionnaire-7 (SAQ-7) to assess disease-specific Quality of Life
EuroQoL 5D (EQ-5D) survey to assess overall health status
(Note: PRO endpoints will be evaluated in the ~2610 subjects of ABSORB IV)
The PROs will be analyzed to evaluate the relationship between quality of life and cardiovascular events that occurred post-PCI and to substantiate the clinical impact of the angina events identified in the trial.
Assessments are made at all time points listed. But overall analysis of QoL is planned to be conducted at the end of the trial.</description>
        <time_frame>3 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Patient Reported Outcomes (PRO)</title>
        <description>Patient-reported outcomes (PRO) are informational endpoints to assess Health-Related Quality of Life. PRO assessments will be conducted at baseline, 1 and 6 months, and at 1, 3 and 5 years.
The following questionnaires will be used in this study:
Seattle Angina Questionnaire-7 (SAQ-7) to assess disease-specific Quality of Life
EuroQoL 5D (EQ-5D) survey to assess overall health status
(Note: PRO endpoints will be evaluated in the ~2610 subjects of ABSORB IV)
The PROs will be analyzed to evaluate the relationship between quality of life and cardiovascular events that occurred post-PCI and to substantiate the clinical impact of the angina events identified in the trial.
Assessments are made at all time points listed. But overall analysis of QoL is planned to be conducted at the end of the trial.</description>
        <time_frame>5 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Landmark Analysis on TLF and Components</title>
        <description>TLF is defined as composite of Cardiac Death, Myocardial Infarction (MI) attributable to Target Vessel (TV-MI), or Ischemia- Driven Target Lesion Revascularization (ID-TLR).</description>
        <time_frame>3-4 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Landmark Analysis on TLF and Components</title>
        <description>TLF is defined as composite of Cardiac Death, Myocardial Infarction (MI) attributable to Target Vessel (TV-MI), or Ischemia- Driven Target Lesion Revascularization (ID-TLR).</description>
        <time_frame>3-5 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Absorb BVS</title>
          <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS)</description>
        </group>
        <group group_id="E2">
          <title>XIENCE</title>
          <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="154" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="120" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ANGINA PECTORIS</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ANGINA UNSTABLE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ARTERIOSCLEROSIS CORONARY ARTERY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ARTERIOSPASM CORONARY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ATRIOVENTRICULAR BLOCK COMPLETE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CARDIAC ARREST</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE CHRONIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE CONGESTIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CARDIOGENIC SHOCK</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY DISSECTION</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY OCCLUSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MITRAL VALVE INCOMPETENCE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MYOPERICARDITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PERICARDITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SICK SINUS SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SUPRAVENTRICULAR TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>VENTRICULAR FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>VENTRICULAR TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DIVERTICULUM INTESTINAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>GASTRITIS EROSIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>GASTROOESOPHAGEAL REFLUX DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>GINGIVAL BLEEDING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>IMPAIRED GASTRIC EMPTYING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PANCREATITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PANCREATITIS CHRONIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>RETROPERITONEAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ADVERSE DRUG REACTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CARDIAC COMPLICATION ASSOCIATED WITH DEVICE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CATHETER SITE HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CHEST DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>COMPLICATION OF DEVICE REMOVAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>NON-CARDIAC CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>THROMBOSIS IN DEVICE</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>BILE DUCT STONE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>DRUG HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>DIVERTICULITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LOBAR PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ACETABULUM FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ANASTOMOTIC ULCER HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CARDIAC PROCEDURE COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CATHETER SITE HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CERVICAL VERTEBRAL FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CONFUSION POSTOPERATIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY RESTENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>IN-STENT CORONARY ARTERY RESTENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>OVERDOSE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PLAQUE SHIFT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PROCEDURAL HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PROCEDURAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PROCEDURAL VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SUBDURAL HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>VASCULAR GRAFT COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>VASCULAR PSEUDOANEURYSM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>BLOOD CREATINE PHOSPHOKINASE MB INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CARDIAC ENZYMES INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ELECTROCARDIOGRAM ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>TROPONIN INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERGLYCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HYPOVOLAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MUSCLE SPASMS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>NECK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>LUNG NEOPLASM MALIGNANT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>APHASIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CENTRAL NERVOUS SYSTEM LESION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CEREBELLAR INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CEREBROVASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>EMBOLIC CEREBRAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>GRAND MAL CONVULSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SENSORY LOSS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SUBARACHNOID HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>CONVERSION DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>DYSURIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>NEPHROLITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>RENAL ARTERY STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>RENAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>URINARY RETENTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CHRONIC OBSTRUCTIVE PULMONARY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DYSPNOEA EXERTIONAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PLEURITIC PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PNEUMONIA ASPIRATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>ANEURYSM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ARTERIAL OCCLUSIVE DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ARTERIOSCLEROSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>FEMORAL ARTERY ANEURYSM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>FEMORAL ARTERY ANEURYSM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HYPERTENSIVE CRISIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HYPERTENSIVE EMERGENCY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>INTERMITTENT CLAUDICATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PERIPHERAL ARTERIAL OCCLUSIVE DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="698" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="703" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LEUKOCYTOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ANGINA PECTORIS</sub_title>
                <counts group_id="E1" subjects_affected="102" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="113" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ANGINA UNSTABLE</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ARTERIOSCLEROSIS CORONARY ARTERY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ARTERIOSPASM CORONARY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ATRIAL FLUTTER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ATRIOVENTRICULAR BLOCK COMPLETE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BRADYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BUNDLE BRANCH BLOCK LEFT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CARDIAC ARREST</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE CHRONIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE CONGESTIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CARDIAC FLUTTER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CARDIOGENIC SHOCK</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY DISSECTION</sub_title>
                <counts group_id="E1" subjects_affected="91" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY OCCLUSION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>EXTRASYSTOLES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LEFT VENTRICULAR DYSFUNCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MITRAL VALVE INCOMPETENCE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MYOPERICARDITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PALPITATIONS</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PERICARDITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SICK SINUS SYNDROME 0.0% (</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SINUS ARREST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SINUS BRADYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SINUS TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SUPRAVENTRICULAR TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>TACHYARRHYTHMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>VENTRICULAR ARRHYTHMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>VENTRICULAR EXTRASYSTOLES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>VENTRICULAR FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>VENTRICULAR TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>ARTERIOVENOUS MALFORMATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>CERUMEN IMPACTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DEAFNESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>EAR HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>VERTIGO</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>HYPOTHYROIDISM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>CONJUNCTIVITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DIABETIC RETINOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DIPLOPIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>EYE HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MACULAR OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>VISION BLURRED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>VISUAL IMPAIRMENT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>VITREOUS HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL DISTENSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN LOWER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DIVERTICULUM INTESTINAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>EPIGASTRIC DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>FAECES DISCOLOURED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>GASTRIC DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>GASTRITIS EROSIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL MOTILITY DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>GASTROOESOPHAGEAL REFLUX DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>GINGIVAL BLEEDING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HAEMATOCHEZIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HAEMORRHOIDS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>IMPAIRED GASTRIC EMPTYING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LIP SWELLING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MOUTH ULCERATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ODYNOPHAGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PANCREATITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PANCREATITIS CHRONIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PARAESTHESIA ORAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>RECTAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>RETROPERITONEAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SPIGELIAN HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ADVERSE DRUG REACTION</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CARDIAC COMPLICATION ASSOCIATED WITH DEVICE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CATHETER SITE HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CATHETER SITE HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CATHETER SITE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CATHETER SITE RASH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CATHETER SITE RELATED REACTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CATHETER SITE SWELLING</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CHEST DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>COMPLICATION OF DEVICE REMOVAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DEVICE FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DEVICE OCCLUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DRUG INTOLERANCE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>GENERALISED OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>IMPAIRED HEALING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>INFLAMMATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>INFUSION SITE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MALAISE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>NON-CARDIAC CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="80" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PACEMAKER GENERATED ARRHYTHMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SENSATION OF FOREIGN BODY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SWELLING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>THROMBOSIS IN DEVICE</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>VESSEL PUNCTURE SITE HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>VESSEL PUNCTURE SITE THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>BILE DUCT STONE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CHOLELITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HEPATIC CYST</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HEPATIC LESION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HEPATIC STEATOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>ALLERGY TO ARTHROPOD BITE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CONTRAST MEDIA ALLERGY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DRUG HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SEASONAL ALLERGY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CATHETER SITE CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CYSTITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DIVERTICULITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HERPES SIMPLEX</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HERPES ZOSTER</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>IMPETIGO</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LOBAR PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LOWER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ORCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>TOOTH INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>VAGINITIS BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>VIRAL UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>WOUND INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ACCIDENTAL OVERDOSE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ACETABULUM FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ANASTOMOTIC ULCER HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ANIMAL BITE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ANKLE FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CARDIAC PROCEDURE COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CATHETER SITE HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CERVICAL VERTEBRAL FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CONFUSION POSTOPERATIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CONTRAST MEDIA ALLERGY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CONTUSION</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY RESTENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DEPRESSION POSTOPERATIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>FOOT FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL DISORDER POSTOPERATIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>IN-STENT CORONARY ARTERY RESTENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>INCORRECT DOSE ADMINISTERED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>JOINT INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>OVERDOSE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PLAQUE SHIFT</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL HAEMATURIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>POST-TRAUMATIC PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE FEVER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PROCEDURAL COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PROCEDURAL DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PROCEDURAL HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PROCEDURAL HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PROCEDURAL HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PROCEDURAL NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PROCEDURAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PROCEDURAL VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ROAD TRAFFIC ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SUBDURAL HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SUTURE RUPTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>TOOTH FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>URINARY RETENTION POSTOPERATIVE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>VASCULAR GRAFT COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>VASCULAR PSEUDOANEURYSM</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>WOUND COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>WRIST FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ARTERIOGRAM CORONARY ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BLOOD CREATINE PHOSPHOKINASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BLOOD CREATINE PHOSPHOKINASE MB ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BLOOD CREATINE PHOSPHOKINASE MB DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BLOOD CREATINE PHOSPHOKINASE MB INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BLOOD CREATININE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BLOOD GLUCOSE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BLOOD LACTIC ACID INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BLOOD POTASSIUM DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BLOOD PRESSURE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BLOOD PRESSURE SYSTOLIC DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BLOOD PRESSURE SYSTOLIC INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BLOOD URINE PRESENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CARDIAC ENZYMES INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="149" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="145" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>EJECTION FRACTION DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ELECTROCARDIOGRAM ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ELECTROCARDIOGRAM ST SEGMENT ELEVATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>FEMORAL BRUIT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>FIBRIN D DIMER INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>INFLUENZA A VIRUS TEST POSITIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LIVER FUNCTION TEST ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>TROPONIN I INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>TROPONIN INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="105" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="84" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>TROPONIN T INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>WEIGHT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>WEIGHT INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>CARBOHYDRATE INTOLERANCE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DIABETES MELLITUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DIABETIC KETOACIDOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>GOUT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HYPERGLYCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HYPERLIPIDAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HYPERTRIGLYCERIDAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HYPOGLYCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HYPOMAGNESAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HYPOVOLAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MALNUTRITION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>METABOLIC ACIDOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>TYPE 2 DIABETES MELLITUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BONE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BURSITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>COSTOCHONDRITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>FLANK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC DEGENERATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>JOINT EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>JOINT STIFFNESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>JOINT SWELLING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LIMB DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MUSCLE SPASMS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MUSCLE TIGHTNESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MUSCLE TWITCHING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MUSCULAR WEAKNESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL STIFFNESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>NECK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PAIN IN JAW</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>RHEUMATOID ARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ROTATOR CUFF SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SYNOVIAL CYST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>TENDONITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>BASAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>COLON ADENOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LIPOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LUNG NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LUNG NEOPLASM MALIGNANT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MENINGIOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>METASTATIC RENAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>APHASIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BASAL GANGLIA INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BASILAR ARTERY STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BRAIN MASS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CAROTID ARTERIOSCLEROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CAROTID ARTERY STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CENTRAL NERVOUS SYSTEM LESION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CEREBELLAR INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CEREBROVASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DIZZINESS POSTURAL</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DRUG WITHDRAWAL HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DYSARTHRIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DYSGEUSIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>EMBOLIC CEREBRAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>GRAND MAL CONVULSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HEAD DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HEAD TITUBATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HYPOAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LETHARGY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MIGRAINE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PARAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PRESYNCOPE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>RADIAL NERVE COMPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SCIATICA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SENSORY LOSS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SOMNOLENCE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SUBARACHNOID HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>TRANSIENT ISCHAEMIC ATTACK</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>VIITH NERVE PARALYSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CONFUSIONAL STATE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CONVERSION DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MENTAL STATUS CHANGES</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PANIC ATTACK</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PERSONALITY DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>BLADDER NECK OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CALCULUS URETERIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DYSURIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HAEMATURIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>NEPHROLITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>POLLAKIURIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>POLYURIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>RENAL ARTERY STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>RENAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>RENAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>URETHRAL MEATUS STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>URINARY BLADDER POLYP</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>URINARY INCONTINENCE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>URINARY RETENTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>URINE FLOW DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>BREAST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ERECTILE DYSFUNCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MENORRHAGIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>VAGINAL HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ASTHMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ATELECTASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CHRONIC OBSTRUCTIVE PULMONARY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DYSPNOEA AT REST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DYSPNOEA EXERTIONAL</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HAEMOPTYSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>OROPHARYNGEAL DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PLEURITIC PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PNEUMONIA ASPIRATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PULMONARY CONGESTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>RHINITIS ALLERGIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SINUS CONGESTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SLEEP APNOEA SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>THROAT IRRITATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>THROAT TIGHTNESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>DERMAL CYST</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DRUG ERUPTION</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ECCHYMOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ERYTHEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HYPERHIDROSIS</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>INCREASED TENDENCY TO BRUISE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LICHEN SCLEROSUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LIVEDO RETICULARIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PETECHIAE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PRURITUS ALLERGIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>RASH GENERALISED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>RASH PRURITIC</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SWELLING FACE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>URTICARIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>ABSCESS DRAINAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CARDIAC PACEMAKER BATTERY REPLACEMENT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>ANEURYSM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>AORTIC INTRAMURAL HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ARTERIAL OCCLUSIVE DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ARTERIAL SPASM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ARTERIOSCLEROSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ARTERIOVENOUS FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>FEMORAL ARTERY ANEURYSM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>FEMORAL ARTERY OCCLUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HYPERTENSIVE CRISIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HYPERTENSIVE EMERGENCY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ILIAC ARTERY OCCLUSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>INTERMITTENT CLAUDICATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ORTHOSTATIC HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PERIPHERAL ARTERIAL OCCLUSIVE DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>REPERFUSION INJURY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>THROMBOPHLEBITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>THROMBOPHLEBITIS SUPERFICIAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>VASOSPASM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Siok Hwee Tan</name_or_title>
      <organization>Abbott Vascular</organization>
      <phone>408-571-9281</phone>
      <email>siokwee.tan@abbott.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

